UCB7853- first doses in humans

• Research type

  Research Study

• Full title

  A Multicenter, Participant-Blind, Investigator-Blind, Randomized, Placebo-Controlled Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses of UCB7853 in Health Male Study Participants and Multiple Ascending Doses in Patients with Parkinson's Disease

• IRAS ID

  1003420

• Contact name

  Malcolm Boyce

• Contact email

  rec@hmrlondon.com

• Eudract number

  2020-003356-32

• Research summary

  Summary of Results
  This was a Phase 1 trial. The plain language summary of results will be disclosed on https://eur03.safelinks.protection.outlook.com/?url=https%3A%2F%2Fclick.pstmrk.it%2F3ts%2Fwww.ucb.com%252Fclinical-studies%252FClinical-studies-index%252FPlain-language-Summaries%2FNBTI%2FWd62AQ%2FAQ%2F09ce270e-a31f-4d12-aa750b82eb023ba9%2F1%2FqeDg9NQXVZ&data=05%7C02%7Capprovals%40hra.nhs.uk%7C1481b1c2ad0d461770f908dcabc2f721%7C8e1f0acad87d4f20939e36243d574267%7C0%7C0%7C638574101064904057%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C0%7C%7C%7C&sdata=eBkJ7UVGfK9gME0IJtOFwWs7ALtPMjLAb2AicpXkOmA%3D&reserved=0 once the clinical results are made available on ClinicalTrials.gov and other registries. The sponsor will also provide the lay summary of study results to the sites so that it can be shared with any participants who are interested in finding out the results.

• REC name

  HSC REC B

• REC reference

  20/NI/0119

• Date of REC Opinion

  11 Nov 2020

• REC opinion

  Further Information Favourable Opinion